Conditions

This post was originally published on this site A Phase 3 trial exploring a combination of Seattle Genetics‘ tucatinib plus standard Kadcyla (ado-trastuzumab emtansine) in people with advanced HER2-positive breast cancer has dosed its first participant, the company announced. The trial — called HER2CLIMB-02 (NCT03975647) — is enrolling up to 460 adult patients with metastatic…

This post was originally published on this site First-line treatment with a combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) added to a shorter course of chemotherapy significantly extends the survival of people with advanced non-small cell lung cancer (NSCLC), compared to standard chemotherapy alone, early Phase 3 trial results show. The CheckMate-9LA trial (NCT03215706)…

This post was originally published on this site U.S. blood cancer specialists are aware of recent approvals for multiple myeloma patients and expect to increase their use of Darzalex (daratumumab) as first-line combination therapy, as well as Xpovio (selinexor) as a fifth-line combination therapy, according to a survey conducted by market research firm Spherix Global Insights. The…

This post was originally published on this site Syros Pharmaceuticals‘ investigational oral inhibitor, SY-5609, can lead to a sustained inhibition of cancer growth in animal models of ovarian cancer and other solid tumors, preclinical data showed. The findings support the initiation of a Phase 1 trial testing the compound early next year, investigators said. Researchers…

This post was originally published on this site Haichong Zhang, an assistant professor at Worcester Polytechnic Institute, has been given a Director’s Early Independence Award from the National Institutes of Health (NIH) to support his work in designing a robotic system to better detect and monitor prostate cancer. Currently, prostate cancer is diagnosed via a blood…

This post was originally published on this site Jazz Pharmaceuticals has enrolled the first participant in a Phase 2 trial assessing the efficacy of Defitelio (defibrotide) to prevent nerve cell toxicity in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are receiving chimeric antigen receptor (CAR) T-cell therapy. The multicenter open-label trial…

This post was originally published on this site Men who father children through assisted reproduction techniques, either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), may be at a higher risk of developing prostate cancer, a study shows. Early screening for prostate cancer may also be beneficial for infertile men, according to the study,…

This post was originally published on this site Decades after establishing the recognized standard for performing and teaching clinical and personal breast exams, the MammaCare Foundation wants women and others to be aware that most breast cancers are found by hand. MammaCare’s goal is to train people what to feel for to identify suspicious breast…

This post was originally published on this site The investigational therapy MDNA55 increases survival in people with recurrent glioblastoma, a type of brain cancer — especially in those who produce high levels of ILR4, a marker of aggressive disease, updated results of a clinical trial show. Fahar Merchant, president and CEO of Medicenna Therapeutics, MDNA55’s…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including financial incentives for therapy development and commercialization, should it be approved. It also provides U.S. market exclusivity for…